로딩 중…
지수 로딩 중…
Kymera Therapeutics, Inc.
KYMR· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$100.31-2.99%
2026-08-03
Financials
Valuation Metrics
Kymera Therapeutics, Inc.'s Market Cap is $8.25B. At end of 2025 it was $6.57B. Ranked #1059 of 3,112 in US market (top 34%), #346 of 1,445 on NASDAQ (top 24%), #55 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 20%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $8.25B | US#1,059/3,112 Sec#55/269 |
| Revenue | $51M | US#2,858/3,112 Sec#155/269 |
| Net Income | $-315M | US—/3,112 Sec—/269 |
| Total Assets | $1.67B | US#2,179/3,112 Sec#57/269 |
| Net Assets | $1.54B | US#1,453/3,112 Sec#43/269 |
| Value | ||
| P/B | 5.36x | US#2,232/3,112 Sec#147/269 |
| P/S | 160.33x | US#2,920/3,112 Sec#187/269 |
| FCF Yield | -2.96% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -20.46% | US#2,528/3,112 Sec#102/269 |
| ROA | -18.88% | US#2,764/3,112 Sec#122/269 |
| Op. Margin | -697.81% | US#2,909/3,112 Sec#171/269 |
| Revenue Growth | 55.50% | US#270/3,112 Sec#53/269 |
| Financial Health | ||
| Debt Ratio | 8.40% | US#85/3,112 Sec#39/269 |
| Total Debt | $80M | US#2,439/3,112 Sec#127/269 |
| FCF | $-244M | US#2,759/3,112 Sec#230/269 |
| Cash | $144M | US#1,962/3,112 Sec#149/269 |
| Current Ratio | 10.81x | US#232/3,112 Sec#73/269 |
| Performance | ||
| 1Y Return | 133.50% | US#196/3,112 Sec#60/269 |
| 1M Return | -11.63% | US#2,683/3,112 Sec#185/269 |
| From 52W High | -22.87% | US#1,850/3,112 Sec#124/269 |
| 1Y MDD | -27.74% | US#1,218/3,112 Sec#72/269 |
| Trading | ||
| Volume | 657,615 shares | US#1,852/3,112 Sec#181/269 |
| Trading Value | $66M | US#1,169/3,112 Sec#69/269 |
| Per Share | ||
| EPS | $-3.69 | US—/3,112 Sec—/269 |
| BPS | $18.72 | US#1,268/3,112 Sec#34/269 |